FY24 Results and Commentary

Strategic Expansion into Regulated Markets

1. Regulated Market Penetration:

• The company has strategically filed for approvals in regulated markets for their existing product portfolio, which previously generated revenue primarily from semi-regulated markets.
• Over time, the company has successfully increased its market share in these regulated markets. This is evidenced by the rise in revenue contribution from regulated markets to 41% of the total topline, up from 31%.

Investment in CMO and CDMO Business

2. CMO and CDMO Expansion:

• Capital Investments: Significant investments are being made in capital expenditures, approvals, and research & development to bolster the CMO (Contract Manufacturing Organization) and CDMO (Contract Development and Manufacturing Organization) segments.
• European Contract: The company has secured a substantial contract with a European company to supply 20-30 tonnes of material this year, with potential revenue peaking at ₹200 crores.
• Future Projects: Two additional projects are in the final stages of approval, promising further growth.
• Market Positioning: By creating a strong brand presence, the company has successfully captured market share from Chinese competitors.
• Vertical Integration: Plans are in place to achieve full backward integration for new niche products, positioning the company as one of the few global manufacturers (excluding a Chinese competitor) capable of producing these products from scratch. This strategy will also facilitate forward integration for certain products.

Product Line Expansion

3. Leveraging Expertise in Anti-Histamines:

• The company is leveraging its expertise in anti-histamines to introduce new products in related fields such as anti-congestants, anti-diabetics, and anti-anxiety medications, which have significant growth potential in targeted geographies.
• Several new products (4-5) are lined up for launch, expanding the company’s product portfolio.

Revenue Guidance and Long-Term Growth Plan

4. Revenue Guidance to ₹1000 Crores by FY27:

• The management has outlined an ambitious plan to achieve a topline of ₹1000 crores by FY27.
• This growth will be driven by increased capacities at existing locations and strategic collaborations.

5. Innovation in Diagnostic Solutions:

• In collaboration with Kalinga University, the company has developed an oral detection kit, which they plan to launch within the next two years.
• Patents have been filed in India, and a partnership with a local company for sales and development has been established.
• Clinical trials are set to commence soon, with expected completion in the next two years.
• There is also significant interest in this product from Southeast Asian countries such as Malaysia, Singapore, and Indonesia.

CAPEX and Capacity Utilization

6. CAPEX and Enhanced Capacity:

• The company plans to invest around ₹100 crores in FY25 for capacity expansion and debottlenecking at the Ambernath plant, Module E.
• Current Capacity: The existing capacity is approximately 597 KL per day.
• Post-CAPEX Capacity: After the planned investments, the capacity will increase to approximately 1020 KL per day at Lote Parshuram and 200 KL per day at Ambernath.
• Utilization: The current capacity utilization is at 86%, the highest level achieved to date.

In summary, the company’s comprehensive growth strategy for FY25 includes expanding into regulated markets, significant investments in CMO and CDMO businesses, leveraging expertise to launch new products, ambitious revenue targets, and substantial CAPEX plans to enhance capacity and utilization. These initiatives position the company for robust growth and increased market presence in the coming years.

Hi Kowshick,

Can you add the detailed balance sheet figures in the “Data sheet” tab of default excel file? This detailed information is only available on the site (as shown below) but is not available in the “Data sheet” tab of excel. The same request goes for the cash flow statement.

This is a real problem, and very difficult to solve.
I think its really very very difficult for an AI Model to solve.

I will definitely, take this to upper levels

I dont see any negative in this type of other income which is related to PLI which will help SBCL to invest more and expand. these type of PLI incomes usually realised in Q4.

Circular trade between add shop e retailer and white organics agro.

The primary criterion for investment is small company, in my opinion, is to examine the promoter’s stake. Avoid investing if the promoter is significantly reducing their stake, even if the company’s fundamentals appear strong and promising.

ASER – 27% from 63%

Surprisingly stock is still trading at 50 cr valuation. Indian retail needs lots of education…

Credit / reference: Twit from Dr Vijay Malik